Axsome Therapeutics (STU:19X) Total Liabilities: €570.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:19X Axsome Therapeutics Inc STU:19X
58 GF Score
Price €205.90
GF Value €188.58
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics Total Liabilities?

Axsome Therapeutics STU:19X +2.98% 58 Total Liabilities is €570.1 Mil as of Mar. 2026. GuruFocus rates STU:19X with a GF Score™ of 58/100 and a GF Value™ of €188.58 (Fairly Valued). The stock has 1 warning sign investors should review.

Axsome Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was €570.1 Mil.

Axsome Therapeutics's quarterly Total Liabilities increased from Sep. 2025 (€507.39 Mil) to Dec. 2025 (€513.69 Mil) and increased from Dec. 2025 (€513.69 Mil) to Mar. 2026 (€570.05 Mil).

Axsome Therapeutics's annual Total Liabilities increased from Dec. 2023 (€364.29 Mil) to Dec. 2024 (€488.47 Mil) and increased from Dec. 2024 (€488.47 Mil) to Dec. 2025 (€513.69 Mil).

Axsome Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Total Liabilities Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.86 209.49 364.29 488.47 513.69

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 502.71 491.34 507.39 513.69 570.05
STU:19X
58GF Score
Axsome Therapeutics Inc STU:19X
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Axsome Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=323.526+(123.944+66.22
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=513.7

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=589.093-75.404
=513.7

Axsome Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=379.918+(126.358+63.776
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=570.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=617.27-47.218
=570.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €570.1 Mil mean?
Axsome Therapeutics (STU:19X) has a Total Liabilities of €570.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Total Liabilities too high?
Axsome Therapeutics' current Total Liabilities is €570.1 Mil. Overall, Axsome Therapeutics has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Total Liabilities compare to MDGL and IONS?
Axsome Therapeutics' Total Liabilities of €570.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Axsome Therapeutics and its competitors. Axsome Therapeutics's current Total Liabilities is €570.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (STU:19X) is currently considered Fairly Valued. The stock's GF Value™ is €188.58, compared to a current price of €205.90 — trading 9.2% above its estimated fair value. The current Total Liabilities is €570.1 Mil. Axsome Therapeutics' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Axsome Therapeutics (STU:19X), the current Total Liabilities is €570.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (STU:19X) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €205.90 is trading 9.2% above its estimated GF Value™ of €188.58. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for STU:19X:

  • Total Liabilities: €570.1 Mil
  • GF Value™: €188.58 vs. price of €205.90 (9.2% above fair value)
  • GF Score™: 58/100 with 1 warning sign

No single metric tells the full story. See the STU:19X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Other Exchanges AXSM:USA1AXSM:Italy0HKF:UK
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
58GF Score

Get the complete analysis for STU:19X

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€205.90
Price
€188.58
GF Value